Italy reconvenes CUD medical devices commission
This article was originally published in Clinica
Italy has reconvened, until July 2010, the medical devices commission (CUD). The February 7 decree establishing its second renewal since 2002 has not changed its remit since taking on the "advisory" roles imposed in its first renewal in 2005. These feature the initiatives launched in 2007 to reclassify the devices available for use by the national health system (SSN), against new reference prices (see Clinica No 1286, p 3). The CUD's core competencies are to direct all national healthcare technology assessment, market regulation, product registration, surveillance and quality R&D activities.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.